Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)
Jaume Capdevila, Alice Durand(Hôpital Edouard Herriot), Nicola Fazio(European Institute of Oncology), Sara Cingarlini, J.C. Ruffinelli(Institut Català d'Oncologia), Côme Lepage(Inserm), Magalie Haissaguerre(Neurocentre Magendie), Jorge Hernando, Javier Molina‐Cerrillo(Hospital Universitario Ramón y Cajal), Francesco Panzuto(Sapienza University of Rome), Paula Jiménez‐Fonseca(Hospital Universitario Central de Asturias), Amparo García-Burillo, Rocio García‐Carbonero(Hospital Universitario 12 De Octubre), Sergio Baldari(University of Messina), Frank Aboubakar Nana(Cliniques Universitaires Saint-Luc), Maddalena Sansovini(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Rosa Álvarez-Álvarez(Hospital General Universitario Gregorio Marañón), Virginia Pubul(Complejo Hospitalario Universitario de Santiago), Teresa Alonso‐Gordoa(Instituto Cajal), Emmanuel Deshayes(Inserm), Angelina Filice(Azienda Sanitaria Unità Locale di Reggio Emilia), C. Ansquer(Centre Hospitalier Universitaire de Nantes), Marta Benavent Viñuales(Instituto de Biomedicina de Sevilla), Laurence Lousberg(Centre Hospitalier Chrétien), Amandine Béron(Centre Hospitalier Universitaire de Lille), B. Fdez Llana(Hospital Universitario Central de Asturias), Maribel Del Olmo-Garcia(Universitat de València), Urbano Anido(Universidade de Santiago de Compostela), Eric Baudin(Institut Gustave Roussy), Maria San‑Roman‑Gil(Hospital Universitario 12 De Octubre), Thomas Walter(Hôpital Edouard Herriot), Alejando García‑Álvarez, Guillermo Villacampa(Vall d'Hebron Institut de Recerca), Timon Vandamme(University of Antwerp), David Taïeb(Aix-Marseille Université)
Cited by 0
Related Papers
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging
|Neuroendocrinology|2017|495
Triple-negative breast cancer: treatment challenges and solutions
|Breast Cancer Targets and Therapy|2016|382
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
|The Lancet|2023|319
Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study
|The Lancet Diabetes & Endocrinology|2020|247